» Articles » PMID: 19015635

Regulation of the HTERT Promoter Activity by MSH2, the HnRNPs K and D, and GRHL2 in Human Oral Squamous Cell Carcinoma Cells

Overview
Journal Oncogene
Date 2008 Nov 19
PMID 19015635
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Higher expression of human telomerase reverse transcriptase (hTERT) and subsequent activation of telomerase occur during cellular immortalization and are maintained in cancer cells. To understand the mode of hTERT expression in cancer cells, we identified cancer-specific trans-regulatory proteins that interact with the hTERT promoter, using the promoter magnetic precipitation assay coupled with mass spectrometry. The identified proteins include MutS homolog 2 (MSH2), heterogeneous nuclear ribonucleoprotein (hnRNP) D, hnRNP K and grainyhead-like 2 (GRHL2). We noticed a higher expression of these proteins in human oral squamous cell carcinoma (OSCC) cells than in normal cells, which do not exhibit telomerase activity. Knockdown of MSH2, hnRNP D and GRHL2 resulted in a notable reduction of the hTERT promoter activity in tested cancer cells. Silencing of the above genes resulted in a significant reduction of the telomerase activity in OSCC cells. Interestingly, among the four identified genes, silencing of GRHL2 was essential in reducing telomerase activity and viability of tested cancer cells. These results suggest a possible role of GRHL2 in telomerase activation during cellular immortalization.

Citing Articles

Prognostic value of blood GRHL2 in patients with non-small-cell lung cancer after radiotherapy and chemotherapy.

Zheng Q, Ji W, Sun R, Dai K Biomark Med. 2024; 18(13-14):611-617.

PMID: 39073846 PMC: 11370899. DOI: 10.1080/17520363.2024.2366161.


GRHL2 Regulation of Growth/Motility Balance in Luminal versus Basal Breast Cancer.

Wang Z, Coban B, Liao C, Chen Y, Liu Q, Danen E Int J Mol Sci. 2023; 24(3).

PMID: 36768838 PMC: 9916895. DOI: 10.3390/ijms24032512.


RNA splicing dysregulation and the hallmarks of cancer.

Bradley R, Anczukow O Nat Rev Cancer. 2023; 23(3):135-155.

PMID: 36627445 PMC: 10132032. DOI: 10.1038/s41568-022-00541-7.


Modifier genes and Lynch syndrome: some considerations.

Scott R Hered Cancer Clin Pract. 2022; 20(1):35.

PMID: 36088367 PMC: 9463843. DOI: 10.1186/s13053-022-00240-2.


GRHL2 Enhances Phosphorylated Estrogen Receptor (ER) Chromatin Binding and Regulates ER-Mediated Transcriptional Activation and Repression.

Reese R, Helzer K, Allen K, Zheng C, Solodin N, Alarid E Mol Cell Biol. 2022; 42(10):e0019122.

PMID: 36036613 PMC: 9584124. DOI: 10.1128/mcb.00191-22.


References
1.
Kang M, Kameta A, Shin K, Baluda M, Park N . Senescence occurs with hTERT repression and limited telomere shortening in human oral keratinocytes cultured with feeder cells. J Cell Physiol. 2004; 199(3):364-70. DOI: 10.1002/jcp.10410. View

2.
Kang M, Kim R, Kim S, Yip F, Shin K, Dimri G . Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer. 2006; 96(1):126-33. PMC: 2360223. DOI: 10.1038/sj.bjc.6603529. View

3.
Campbell M, Wang Y, Andrew S, Liu Y . Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect. Oncogene. 2005; 25(17):2531-6. DOI: 10.1038/sj.onc.1209277. View

4.
Deng W, Jayachandran G, Wu G, Xu K, Roth J, Ji L . Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem. 2007; 282(36):26460-70. DOI: 10.1074/jbc.M610579200. View

5.
Lebel R, McDuff F, Lavigne P, Grandbois M . Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter. Biochemistry. 2007; 46(36):10279-86. DOI: 10.1021/bi700076m. View